The absence of KIT mutations necessitates a thorough evaluation for other genetic abnormalities, such as mutations in ASXL1, RUNX1, and SRSF2, which are known to impact prognosis and survival in SM-AML adversely [25]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.